+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharyngitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 131 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5969987
The 7 major pharyngitis markets reached a value of US$ 1.6 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 2.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.11% during 2023-2034.

The pharyngitis market has been comprehensively analyzed in this report titled "Pharyngitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pharyngitis refers to a medical condition that causes inflammation or infection of the pharynx, which is the part of the throat located behind the nasal cavity and mouth. The most common symptom of the ailment is a sore throat that may be accompanied by pain or discomfort while swallowing. Numerous other indications of this disease include redness and swelling of the throat, inflammation of the tonsils, swollen lymph nodes in the neck, hoarseness or a scratchy voice, coughing, runny nose, sneezing, body aches, headaches, fever, etc. The diagnosis of pharyngitis usually involves a physical examination, evaluation of symptoms, and sometimes a throat swab to determine the presence of bacteria or viruses. Additionally, several blood tests may be performed to assess the general health of the patient and check for indications of the infection. These investigations can measure various parameters, such as white blood cell count and C-reactive protein (CRP) levels. A healthcare provider may further conduct polymerase chain reaction (PCR) testing to detect the genetic material of the pathogen causing the condition.

The increasing cases of viral and bacterial infections, which invade the healthy cells in the lining of the throat and tonsils, leading to inflammation and irritation, are primarily driving the pharyngitis market. In addition to this, the rising prevalence of exposure to dry air, smoking, pollution, etc., or numerous other environmental irritants, like allergens and strong fumes, that can directly damage the pharyngeal tissues, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), antivirals, antibiotics, etc., to treat the ailment or manage the disease symptoms is further bolstering the market growth. Apart from this, the inflating application of throat lozenges or sprays, which contain numbing agents like benzocaine and menthol to relieve discomfort and pain by soothing the irritated tissues, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of photobiomodulation therapy, since it uses light-emitting diodes or low-level lasers to stimulate cellular function in patients and promote healing, is expected to drive the pharyngitis market during the forecast period.

This report provides an exhaustive analysis of the pharyngitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pharyngitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pharyngitis market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the pharyngitis market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the pharyngitis market

Competitive Landscape:

This report also provides a detailed analysis of the current pharyngitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
  • Drugs Company Name
  • Moxatag (Amoxicillin extended-release) MiddleBrook
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the pharyngitis market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the pharyngitis market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the pharyngitis market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of pharyngitis across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of pharyngitis by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of pharyngitis by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with pharyngitis across the seven major markets?
  • What is the size of the pharyngitis patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of pharyngitis?
  • What will be the growth rate of patients across the seven major markets?

Pharyngitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for pharyngitis drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pharyngitis market?
  • What are the key regulatory events related to the pharyngitis market?
  • What is the structure of clinical trial landscape by status related to the pharyngitis market?
  • What is the structure of clinical trial landscape by phase related to the pharyngitis market?
  • What is the structure of clinical trial landscape by route of administration related to the pharyngitis market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

?1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Pharyngitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Pharyngitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Pharyngitis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 Pharyngitis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Pharyngitis - Unmet Needs10 Pharyngitis - Key Endpoints of Treatment
11 Pharyngitis - Marketed Products
11.1 List of Pharyngitis Marketed Drugs Across the Top 7 Markets
11.1.1 Moxatag (Amoxicillin extended-release) - MiddleBrook
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report
12 Pharyngitis - Pipeline Drugs
12.1 List of Pharyngitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name - Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. Pharyngitis - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Pharyngitis - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Pharyngitis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pharyngitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pharyngitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pharyngitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pharyngitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pharyngitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pharyngitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pharyngitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pharyngitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pharyngitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pharyngitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pharyngitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pharyngitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pharyngitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pharyngitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pharyngitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pharyngitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pharyngitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pharyngitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pharyngitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pharyngitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pharyngitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pharyngitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pharyngitis - Access and Reimbursement Overview
16 Pharyngitis - Recent Events and Inputs From Key Opinion Leaders
17 Pharyngitis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Pharyngitis Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...

Table Information